HedgeChatter

  • Home /
  • Tag Archives

TTHI

Transition Therapeutics Announces Enrollment of the First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer’s Disease

[at noodls] – – Approximately 90% of AD patients develop neuropsychiatric symptoms – Approximately 60% of AD patients develop agitation/aggression TORONTO, ON, November 28th, 2012 – Transition Therapeutics Inc. (Transition … moreView todays social media effects on TTHIView the latest stocks trending across Twitter. Click to view dashboard […]

November 28, 2012 Bystocknews , Comments Off on Transition Therapeutics Announces Enrollment of the First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer’s Disease read more

Transition Therapeutics Announces First Quarter Fiscal 2013 Financial Results

[at noodls] – TORONTO, ON, November 8, 2012 – Transition Therapeutics Inc. (Transition or the Company) (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics … moreView todays social media effects on TTHIView the latest stocks trending across Twitter. Click to view dashboard […]

November 9, 2012 Bystocknews , Comments Off on Transition Therapeutics Announces First Quarter Fiscal 2013 Financial Results read more

Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2013 Financial Results on Thursday, November 8th, at 4:30 P.M. EST

[at noodls] – TORONTO, ON, November 5th, 2012 – Transition Therapeutics Inc. (Transition or the Company) (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Thursday, November 8th, 2012 at … moreView todays social media effects on TTHIView the latest stocks trending across Twitter. Click to view dashboard […]

November 6, 2012 Bystocknews , Comments Off on Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2013 Financial Results on Thursday, November 8th, at 4:30 P.M. EST read more